Epidemiology of Mantle lymphoma in a reference hospital in the Amazon
DOI:
https://doi.org/10.33448/rsd-v12i1.39798Keywords:
Mantle Cell Lymphoma; Epidemiology; Non-Hodgkin Lymphoma.Abstract
Mantle cell lymphoma is a rare and aggressive mature B-cell non-Hodgkin lymphoma (NHL) with historically low long-term survival rates. The objective of the study was to outline the epidemiological profile of patients diagnosed with Mantle Cell Lymphoma treated at a reference cancer hospital. An observational, descriptive, cross-sectional study was carried out, with analysis of hospital records. Most patients were male, aged between 60 and 69 years and in stage IV. There was a predominance of patients with B symptoms. In laboratory terms, the patients had elevated lactic dehydrogenase and leucometry. No correlation was identified between age, lactic dehydrogenase and leukometry with mortality, on the other hand, there was a positive correlation with staging. All subjects had high-risk MIPI stratification. All first-line therapies were based on chemotherapy associated with the anti-CD20 monoclonal antibody – Rituximab. The second-line therapies used were: DHAP and GDP. Half of the patients underwent a second line of treatment. 100% of the patients studied did not undergo autologous transplantation, which may have influenced the status of patients in which 60% died. Future studies are needed to establish the impact on patient survival from changes in applied therapy such as increased exposure to autologous transplantation or use of covalent inhibitors of Bruton's tyrosine kinase (BTK).
References
Armitage, J. O & Longo, D. L. (2022). Mantle cell lymphoma. N Engl J Med. 386 (26), 2495-2506.
Assis-Mendonça, G. R., Crepaldi, A. H., Delamain, M. T., Moreira, A. H., Costa, F. D., Lima, V. C. C. et al. (2018). Characteristics of follicular and mantle cell lymphoma in Brazil: prognostic impact of clinical parameters and treatment conditions in two hospitals. Hemato Tranfus Cell Ther. 40 (40, 343-353.
Aukema, S. M., Hoster, E., Rosenwald, A. et al. (2018). Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki‐67 in trials of the European MCL Network. Blood. 131 (4), 417‐420.
Barouch, S. B., Kuruvilla, J., Tsang, R. W., Yashphe, E & Sarid, N. (2020). Radiotherapy in mantle cell lymphoma: a literature review. Hematol Oncol. 38 (3), 223-228.
Brasil, S. A. B., Colaço, C., Barrese, T., Paes, R. P., Brotolheiro, C & Cancadi, R. D. (2020). Non-indolent mantle cell lymphoma at a single public hospital in Brazil: real world first-line treatment cohort study data. Hemato Tranfus Cell Ther. 42 (1), 93-97.
Burkart, M & Karmali, R. (2022). Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors. J. Pers. 12 (376), 1-14.
Cheah, C. Y., George, A., Gine, E., Chiappella, A., Kluin-Nelemans, H. C., Jurczak, W., Krawczyk, K., Mocikova, H., Klener, P., Salek, S. et al. (2013). European Mantle Cell Lymphoma Network. Central nervous system involvement in mantle cell lymphoma: Clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann. Oncol. 24, 2119–2123.
Cheah, C. Y., Seymour, J. F & Wang, M. L. (2016). Mantle cell lymphoma. J Clin Oncol. 34 (11), 1256–1269.
Cronin, P., Ryan, F & Coughlan, M. (2008). Undertaking a literature review: a step-by-step approach. Br J Nurs. 17 (1), 38-43.
Das, C. K., Gogia, A., Kumar, L., Sharma, A., Sharma, M. C & Mallick, S. R. (2016). Mantle cell lymphoma: a north Indian tertiary care centre experience. Asian Pacific Journal of Cancer Prevention. 17, 4583-4586.
Davids, M. S., Roberts, A. W., Seymour, J. F. et al. (2017). Phase I first-in-human study of Venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 35 (8), 826-833.
Dreyling, M. (2014). European Mantle Cell Lymphoma Network Mantle cell lymphoma: Biology, clinical presentation, and therapeutic approaches. Am. Soc. Clin. Oncol. Educ. Book. 34, 191–198.
Dreyling, M., Campo, E, Hermine, O. et al (2017). Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 28 (4), 62‐71.
Dreyling, M., Jurczak, W., Jerkeman, M. et al. (2016). Ibrutinib versus Temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 387 (10020), 770-778.
Fisher, R. I., Bernstein, S. H., Kahl, B. S. et al. (2006). Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 24 (30), 4867-4874.
Goy, A., Sinha, R., Williams, M. E. et al. (2013). Single-agent Lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to Bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 31 (29), 3688-3695.
Horesh, N & Horowitz, N. A. (2014). Does gender matter in Non-Hodgkin Lymphoma? Differences in epidemiology, clinical behavior and therapy. Rambam Maimonides Med J. 5 (4).
Hoster, E., Kluin-Nelemans, H., Hermine, O. et al. (2017). Rituximab maintenance after first-line immunochemotherapy in mantle cell lymphoma: long-term follow-up of the randomized European MCL Elderly Trial. Blood. 130 (1), 153-153.
Instituto Nacional De Câncer José Alencar Gomes Da Silva (INCA). Estimativa 2020: incidência de câncer no Brasil/ Instituto Nacional de Câncer José Alencar Gomes da Silva. – Rio de Janeiro: INCA, 2019.
Isaac, K. M., Portell, C. A & Williams, M. E. (2021). Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management. Current Oncology Reports. 23 (102), 1-6.
Jain, P & Wang, M. (2022). Mantle cell lymphoma in 2022 – A comprehensive update on molecular pathogenesis, risk stratifications, clinical approach, and current and novel treatments. Am J Hematol. 97 (5), 638-656.
Jain, P & Wang, M. (2019). Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol. 94 (6), 710–725.
Jares, P., Colomer, D & Campo, E. (2012). Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 122 (10), 3416‐3423.
Lecluse, Y., Lebailly, P., Roulland, S., Gac, A. C., Nadel, B & Gauduchon, P. (2009). t (11,14) positive clones can persist over a long period of time in the peripheral blood of healthy individuals. Leukemia. 23, 1190-1193.
Lee, C & Martin, P. (2020). Watch and Wait in Mantle Cell Lymphoma. Hematol Oncol Clin N Am. 34, 837-847.
Leux, C., Maynadie, M., Troussard, X., Cabrera, Q., Herry, A., Guyader-Peyrou, S.L., Gouill, S.L., Monnereau, A. Mantle cell lynphoma epidemiology: a population-based study in France. Ann Hematol. 2014.
Li, S., Xu, J & You, M. J. (2021). The pathologic diagnosis of mantle cell lymphoma. Histol Histopathol. 36 (10), 1037-1051.
Martin, P., Ghione, P & Dreyling, M. (2017). Mantle cell lymphoma - current standards of care and future directions. Cancer Treat Rev. 58, 51–60.
Martins, C., Teixeira, C., Gamito, E & Oliveira, A. P. (2017). Mantle cell lymphoma presenting as multiple lymphomatous polyposis of the gastrointestinal tract. Rev Bras Hematol Hemoter. 39 (1), 73-76.
Mori, S., Patel, R. D., Ahmad, S., Varela, J., Smith, T., Altoos, R., Shen, Q., Goldstein, S. C & Persky, D. O. (2019). Aggressive leukemic non-nodal mantle cell lymphoma with p53 gene rearrangement/mutation is highly responsive to rituximab/ibrutinib combination therapy. Clinical Lymphoma, Myeloma & Leukemia. 19 (2), 93-97.
Mostaghel, E. A., Martin, P. S., Mongovin, S., Frayo, S., Zhang, A., Edlefson, K. L., Press, O. W & Gopal. A. K. (2017). Androgen Receptor expression in mantle cell lymphoma: potential novel therapeutic implications. Experimental Hematology. 49, 34-38.
Nabrinsky, E., Danilov, A. V & Koller, P. B. (2021). High-risk mantle cell lymphoma in the era of novel agents. Curr Hematol Malig Rep. 16 (1), 8-18.
Narkhede, M., Goyal, G., Shea, L., Mehta, A & Gin, S. (2022). Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. Blood Advances. 6 (14), 4122-4131.
Quintanilla-Martinez, L., Davies-Hill, T., Fend, F., Calzada-Wack, J., Sorbara, L., Campo, E., Jaffe, E. S & Raffeld, M. (2003). Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood. 101, 3181-3187.
Robak, T., Smolewski, P., Robak, P. & Dreyling, M. (2019). Mantle cell lymphoma: therapeutic options in transplant-ineligible patients. Leuk Lymphoma. 60 (11), 2622-2634.
Rocha, E. A. C. (1999). A pesquisa em educação infantil no Brasil: trajetória recente e perspectiva de consolidação de uma pedagogia da educação infantil. Florianópolis: UFSC, Centro de Ciências da Educação, Núcleo de Publicações.
Rosenberg, S.A. (1996). Report of the committee on the staging of Hodgkin’s disease. Cancer Research. 26 (1310).
Schollkopf, C., Melbye, M., Munksgaard, L. et al. (2008). Borrelia infection and risk of non-Hodgkin lymphoma. Blood. 111 (12).
Silkentedt, E. & Dreyling, M. (2021). Mantle cell lymphoma – Advances in molecular biology, prognostications and treatmente approaches. Hematol Oncol. 39 (1), 31-38.
Skibola, C. F., Bracci, P. M., Nieters, A. et al. (2010). Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non- Hodgkin lymphoma in the InterLymph consortium. Am J Epidemiol. 171 (3), 267-276.
Smedby, K. E., Sampson, J. N., Turner, J. J. et al. (2014). Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: the interlymph non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 48, 76-86.
Smith, A., Howell, D., Patmore, R., Jack, A & Roman, E. (2011). Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network. Br. J. Cancer. 105, 1684–1692.
Smolewski, P., Rydygier, D & Robak, T. (2019). Clinical management of mantle cell lymphoma in the elderly. Expert Opin Phrmacother. 20 (15), 1893-1905.
Stone, R. (2018). Male-Female differences in the prevalence of Non-Hodgkin Lymphoma and residential proximity to superfund sites in Kentucky. Journal of Environmental Health. 81 (3), 15-24.
Swerdlow, S., Campo, E., Harris, N., Jaffe, E., Pileri, S., Stein, H. et al (2017). WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC.
Swerdlow, S., Campo, E., Pileri, S., Harris, N., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G., Zelenetz, A & Jaffe, E. (2016). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 127, 2375-2390.
Wallace, D. & Reagan, P. M. (2021). Novel treatments for mantle cell lymphoma: from targeted therapies to CAR T cells. Drugs. 81 (6), 669-684.
Wang, S. S., Slager, S. L., Brennan, P. et al. (2007). Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the inter- national lymphoma epidemiology consortium (InterLymph). Blood. 109 (8), 3479-3488.
Yang, X., Khoo, L. P., Chang, E. W. Y., Yang, V. S., Poon, E., Somasundaram, N. et al. (2021). Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian population. BMC Cancer. 21 (566), 1-10.
Zhou, Y., Wang, H., Fang, W. et al. (2008). Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 113, 791–798.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Vitória de Souza Siqueira; Ana Virginia Soares Van den Berg
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
